Izba (Travoprost)

Travoprost binds to prostaglandin F (FP) receptors in the eye’s ciliary body. This activation enhances uveoscleral outflow of aqueous humor, increasing drainage from the anterior chamber and resulting in a sustained reduction of intraocular pressure.

The dosing regimen for Izba is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for travoprost in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To request Izba, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Izba (travoprost) belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intraocular pressure reduction. Compared with beta‑blocker drops, prostaglandin analogs tend to have a more favorable dosing schedule and comparable efficacy, though individual response may vary.

Store Izba eye‑drop bottles at room temperature, away from direct sunlight and moisture. Keep the container tightly closed when not in use and retain it in the original packaging to protect the solution from contamination.

Tilt the head back slightly, pull down the lower eyelid to create a small pocket, and instill one drop of Izba into the conjunctival sac. Close the eye gently for a few seconds, avoid touching the tip of the bottle to the eye or any surface, and wash hands afterward.

Serious but rare adverse events include macular edema, anterior uveitis, and severe allergic reactions such as swelling or rash around the eye. Patients should seek immediate medical attention if they experience sudden vision changes, eye pain, or signs of an allergic response.

Izba should not be used by individuals with known hypersensitivity to travoprost or any component of the formulation, and it is contraindicated in eyes with active intraocular infection or inflammation. Caution is also advised for patients with a history of cystoid macular edema.